Agenus logo

AgenusNASDAQ: AGEN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 February 2000

Next earnings report:

14 March 2025

Last dividends:

N/A

Next dividends:

N/A
$62.17 M
-93%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
14%vs. sector
-96%vs. 3y high
10%vs. sector

Price

after hours | Tue, 19 Nov 2024 23:39:01 GMT
$2.65+$0.01(+0.38%)

Dividend

No data over the past 3 years
$25.11 M$33.37 M
$25.11 M-$66.39 M

Analysts recommendations

Institutional Ownership

AGEN Latest News

Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
zacks.com15 November 2024 Sentiment: POSITIVE

Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates
zacks.com12 November 2024 Sentiment: NEGATIVE

Agenus (AGEN) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $2.10. This compares to loss of $3.20 per share a year ago.

November 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AGEN
accesswire.com05 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110801&wire=1 or contact Joseph E. Levi, Esq.

Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN
accesswire.com05 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110719&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about pending Class Action - AGEN
prnewswire.com05 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 5, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024.

Class Action Filed Against Agenus Inc. (AGEN) Seeking Recovery for Investors – Contact Levi & Korsinsky
accesswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110658&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Agenus Inc. (AGEN) - November 5, 2024 Deadline to Join – Contact Levi & Korsinsky
globenewswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.

Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN
accesswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110613&wire=1 or contact Joseph E. Levi, Esq.

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders
prnewswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 4, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Investors Who Lost Money on Agenus Inc. (AGEN) Should Contact Levi & Korsinsky About Pending Class Action - AGEN
accesswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110633&wire=1 or contact Joseph E. Levi, Esq.

What type of business is Agenus?

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

What sector is Agenus in?

Agenus is in the Healthcare sector

What industry is Agenus in?

Agenus is in the Biotechnology industry

What country is Agenus from?

Agenus is headquartered in United States

When did Agenus go public?

Agenus initial public offering (IPO) was on 08 February 2000

What is Agenus website?

https://www.agenusbio.com

Is Agenus in the S&P 500?

No, Agenus is not included in the S&P 500 index

Is Agenus in the NASDAQ 100?

No, Agenus is not included in the NASDAQ 100 index

Is Agenus in the Dow Jones?

No, Agenus is not included in the Dow Jones index

When was Agenus the previous earnings report?

No data

When does Agenus earnings report?

The next expected earnings date for Agenus is 14 March 2025